Radiolabeled tirofiban-a potential radiopharmaceutical for detection of deep venous thrombosis

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 2989-2996

  Darkovska Serafimovska, Marija ^a,d   Janevik Ivanovska, Emilija ^a   Djorgoski, Icko ^b   Arsova Sarafinovska, Zorica ^a,c   Zdravkovska, Milka ^a   Balkanov, Trajan ^b   Ugresic, Nenad ^d  

^a GOCE DELCEV UNIVERSITY   (Macedonia)

^b SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^c Institute of Public Health   (Macedonia)

^d UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

99mtechnetium; Deep venous thrombosis; Tirofiban; Visualization

Indexed keywords

ADENOSINE DIPHOSPHATE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; TECHNETIUM 99M; TIROFIBAN; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; RADIOPHARMACEUTICAL AGENT; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; ISOTOPE LABELING; MALE; NONHUMAN; RADIOACTIVITY; RAT; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA; WHOLE BODY SCINTISCANNING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG EFFECTS; VEIN THROMBOSIS; WISTAR RAT;

ADENOSINE DIPHOSPHATE; ANIMALS; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; TYROSINE; VENOUS THROMBOSIS;

EID: 84988932706     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S112366     Document Type: Article

References (38)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992; 326(4): 242-250.
2. Jagroop IA, Mikhailidis DP. The effect of Tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation. Clin Appl Thromb Hemost. 2008; 14(3): 295-302.
3. Christie DJ, Avari T, Carrington LR, et al. Platelet Function Testing by Aggregometry: Approved Guideline. CLSI Guideline H58-A (ISBN 1-56238-683-2). Clinical and Laboratory Standards Institute, Wayne, PA; 2008.
4. Hayward CP, Moffat KA, Rab A, et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol. 2010; 134: 955-963.
5. Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science. 2010; 328(5978): 562-564.
6. Brass L. Understanding and evaluating platelet function. Hematology Am Soc Hematol Educ Program. 2010; 2010: 387-396.
7. Picker SM. In-vitro assessment of platelet function. Transfus Apheresis Sci. 2011; 44(3): 305-319.
8. Giordano A, D’Angelillo A, Romano S, et al. Tirofiban induces VEGF production and stimulates migration and proliferation of endothelial cells. Vascul Pharmacol. 2014; 61(2-3): 63-71.
9. Hashemzadeh M, Furukawa M, Goldsberry S, Movahed MR. Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: a review. Exp Clin Cardiol. 2008; 13(4): 192-197.
10. Jayasundera TG, Feldman DN, Marmur JD. Tirofiban-induced coronary thrombosis. J Invas Cardiol. 1999; 11(3): 138-140.
11. Lannetta L, Puddu PE, Cuturello D, Saladini A, Pellicano M, Schiariti M. Is there still a role for glycoprotein IIb/IIIa antagonists in acute coronary syndromes? Cardiol Res. 2013; 4(1): 1-7.
12. King S, Short M, Harmon C. Glycoprotein IIb/IIIa inhibitors: the resurgence of tirofiban. Vascul Pharmacol. 2016; 78: 10-16.
13. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman’s, The Pharmacological Basis of Therapeutics. 11th ed. New York: The McGraw Hill Co.; 2006.
14. Kumar A, Herrmann HC. Tirofiban: an investigational platelet glycoprotein IIb/IIIa receptor antagonist. Expert Opin Investig Drugs. 1997; 6(9): 1257-1267.
15. Anon. Tirofiban hydrochloride. Drugs Future. 1995; 20: 897-901.
16. http://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20912lbl.pdf. Accessed October 24, 2014.
17. Medicure Pharma. Aggrastat (Tirofiban Hydrochloride) Injection Premixed and Injection Prescribing Information. Somerset, NJ: Medicure Pharma; 2007.
18. Darkovska Serafimovska M, Janevik-Ivanovska E, Arsova-SarafinovskaZ, Djorgoski I, Ugresic N. Development and validation of reverse phase high performance liquid chromatographic method for determination of tirofiban in serum. Int J Pharm. 2014; 4(4): 115-120.
19. Kulkarni S, Dopheide SM, Yap CL, et al. A revised model of platelet aggregation. J Clin Invest. 2000; 105(6): 783-791.
20. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay - an automated and quantitative cartridge-based method. Circulation. 1999; 99(5): 620-625.
21. Holmes MB, Kubbani S, Terrien C, Sobel B, Schneider D. Quantification by flow cytometry of the efficacy and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab. Coron Artery Dis. 2001; 12(3): 245-253.
22. Simon DI, Liu CB, Ganz P, et al. A comparative study of light transmission aggregometry and automated bedside platelet function assay in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibrate, or tirofiban. Catheter Cardiovasc Interv. 2001; 52(4): 425-432.
23. Lister-James J, Mauer A. Thrombus imaging with a technetium 99m labeled, activated platelet receptor binding peptide. J Nucl Med. 1996; 213: 207.
24. Pearson DA, Lister-James J, McBride WJ, et al. Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies. J Med Chem. 1996; 39(7): 1372-1382.
25. Callas JW, Fareed DDJ. A survey of animal models to develop new and novel antithrombotic agents. In: Sasahara AA, Loscalzo JL, editors. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker; 1997: 9-28.
26. Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood. 1992; 80(9): 2281-2286.
27. Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with Tirofiban or eptifibatide is associated with antibodies specific for ligandoccupied GPIIb/IIIa. J Am Soc Hematol. 2002; 100(6): 2071-2076.
28. Hardoff R, Braegelmann F, Zanzonico P, et al. External imaging of atherosclerosis in rabbits using an 123 I-labeled syntetic peptide fragment. J Clin Pharmacol. 1993; 33(11): 1039-1047.
29. Konstantinides S, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35(43): 3033-3069.
30. Kearon C, Akl E, Comerota AJ, et al. Antithrombotic therapy for VTE disease. Chest. 2012; 141(2 suppl): e419S-e494S.
31. National Institute for Health and Clinical Excellence. Venous Thromboembolic Disease: the Management of Venous Thromboembolic Disease of Thrombophilia Testing. Clinical Guideline. Methods Evidence and Recommendations; London 2012.
32. Janevic E, Tadzer IS. Tc-99m labelling of platelets using diethyl-dithiocarbamate or 2,5-dihydroxy-benzoic acid. Period Biol. 1989; 91: 409-411.
33. Schneider DJ. Anti-platelet therapy: glycoprotein IIbIIIa antagonists. Br J Clin Pharmacol. 2011; 72(4): 672-682.
34. Trajkovski R, Milenkov V, Dukovski R, Janevic E, Tadžer IS. Obeležavanje humanih trombocita sa dietill-ditiokarbamat Tc-99m (DDC). Bilten Hemat Transf. 1989; 17: 21-25.
35. van Rensburg WJ, Roodt JP, Lamprecht S, Meiring SM, BadenhorstPN. Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates. Clin Exp Med. 2012; 12(4): 257-263.
36. Yeung J, Holinstat M. Newer agents in antiplatelet therapy: a review. J Blood Med. 2012; 3: 33-42.
37. Darkovska SM, Janevik-Ivanovska E, Ugresic N, Djorgoski I. Imaging of deep venous thrombosis using radioactive-labeled tirofiban. Bratisl Med J. 2015; 116(10): 621-626, 6.
38. Vickers S, Theoharides AD, Arison B, et al. In vitro and in vivo studies on the metabolism of tirofiban. Drug Metab Dispos. 1999; 27(11): 1360-1366.